PLSE begins patient enrollment in NANOPULSE-AF pivotal study, advancing its NPS tech toward potential AF treatment approval ...

Atrial fibrillation (AF), the most common cardiac arrhythmia, affects approximately 3-6 million people in the United States — a figure expected to increase to around 6-16 million by 2050. Globally, ...

Atrial fibrillation treatment with device closure matched anticoagulants and reduced bleeding risk. Discover what this means for AF care.

An individually tailored multidimensional risk-based treatment strategy was not associated with improvements in clinical outcomes compared with usual guideline-based care in patients with atrial ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced it expanded its Phase III OCEANIC clinical development program for the investigational drug asundexian (BAY2433334) by initiating a third ...

Atrial fibrillation is a common heart condition characterized by a rapid, irregular heartbeat stemming from the heart's upper chamber. It is a leading cause of stroke from clots that form in a small ...

MADRID, Spain—A tailored treatment strategy based on the ABC-AF stroke and bleeding risk scores is no better than usual care for patients with atrial fibrillation (AF) and a low-to-moderate risk of ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Previously, patients with advanced atrial fibrillation (AF ...

The Christus Health Louis and Peaches Owen Heart Hospital in Tyler on Monday became one of the first sites in the nation to ...

In the year following successful treatment of atrial fibrillation (AF) by catheter ablation, kidney function improves in patients with mild to moderate renal dysfunction, Yoshihide Takahashi, MD, and ...